Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 7Hematologic Neoplasms 4Waldenstrom Macroglobulinemia 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma 2Leukemia, B-Cell 2Vascular Diseases 1Recurrence 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Mature B-cell Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphatic Diseases 1Leukemia, Lymphoid 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hemostatic Disorders 1Hemorrhagic Disorders 1Dendritic Cell Sarcoma, Interdigitating 1Cardiovascular Diseases 1Blood Protein Disorders 1

Interventions

Cyclophosphamide 447Rituximab 406Etoposide 225Vincristine 217Doxorubicin 204Filgrastim 201Prednisone 178Cytarabine 160Radiotherapy 152fludarabine phosphate 148Methotrexate 137Peripheral Blood Stem Cell Transplantation 130Melphalan 128fludarabine 116Busulfan 101Dexamethasone 93Tacrolimus 76Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 72Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 63Bendamustine Hydrochloride 63Lenalidomide 62Cyclosporine 62Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × ARQ531 × Clear all
NCT07583810 2026-05-15

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

City of Hope Medical Center

Phase 2 Not yet recruiting
35 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT03162536 2025-09-08

ARQ 531-101

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1/2 Active not recruiting
190 enrolled
LymphoidOther hematologic neoplasmPlasma cellSarcoma

Blood Protein Disorders, Cardiovascular Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Recurrence, Vascular Diseases, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Hemostatic Disorders, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡